Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rhabdoid Tumor of the Kidney and Soft Tissues: Results from National Wilms Tumor Study-5 and Children's Oncology Group Study AREN0321.

Pediatric blood & cancer·2024
Same author

Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.

Journal of pediatric surgery·2024
Same author

ASO Video Abstract: Kidney Preservation and Wilms Tumor Development in Children with Diffuse Hyperplastic Perilobar Nephroblastomatosis-A Report from the Children's Oncology Group Study AREN0534.

Annals of surgical oncology·2022
Same author

Kidney Preservation and Wilms Tumor Development in Children with Diffuse Hyperplastic Perilobar Nephroblastomatosis: A Report from the Children's Oncology Group Study AREN0534.

Annals of surgical oncology·2022
Same author

Results of Treatment for Patients With Multicentric or Bilaterally Predisposed Unilateral Wilms Tumor (AREN0534): A report from the Children's Oncology Group.

Cancer·2020
Same author

Imaging Characteristics of Nephrogenic Rests Versus Small Wilms Tumors: A Report From the Children's Oncology Group Study AREN03B2.

AJR. American journal of roentgenology·2020
Same journal

Widely available, general-purpose generative AI applications for radiology education: determining the teaching quality of synthetic pediatric neuroradiology images.

Pediatric radiology·2026
Same journal

Sustainability: a physician's cautionary tale.

Pediatric radiology·2026
Same journal

The invisible footprint: why planetary health is a pediatric radiologist's obligation.

Pediatric radiology·2026
Same journal

The radiographic bubbly fecal pattern of intestinal pneumatosis in newborns revisited.

Pediatric radiology·2026
Same journal

Regional differences in fetal fat accretion in small-for-gestational-age fetuses assessed by quantitative magnetic resonance imaging.

Pediatric radiology·2026
Same journal

Thermal ablation of lung metastases in children: what every paediatric radiologist should know.

Pediatric radiology·2026
See all related articles

Related Experiment Video

Updated: Jun 2, 2026

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

Interventional oncology: the future.

Fredric A Hoffer1

  • 1Department of Radiology, University of Washington, 3904 NE Belvoir Place, Seattle, WA 98105, USA. fhoffer@gmail.com

Pediatric Radiology
|April 28, 2011
PubMed
Summary
This summary is machine-generated.

Interventional oncology (IO) offers valuable treatments for adult cancers but faces challenges in pediatric applications. Overcoming these hurdles will expand IO benefits for treating childhood malignancies.

Related Experiment Videos

Last Updated: Jun 2, 2026

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

Area of Science:

  • Pediatric oncology
  • Interventional radiology
  • Medical device development

Background:

  • Interventional radiology techniques are established for adult cancer treatment.
  • Adoption of interventional oncology (IO) in pediatric cancer care is limited.
  • Challenges include regulatory approval, protocol restrictions, and hesitancy in using novel pediatric treatments.

Purpose of the Study:

  • To discuss the development and approval processes for new interventional oncology procedures.
  • To highlight emerging therapies for pediatric malignancies.
  • To advocate for the expansion of interventional oncology in pediatric care.

Main Methods:

  • Review of current literature on interventional oncology in adults and children.
  • Analysis of regulatory pathways for medical devices and agents in pediatric oncology.
  • Discussion of strategies to facilitate the adoption of new IO therapies in pediatric settings.

Main Results:

  • The paper outlines the complexities in approving new IO devices and agents for pediatric use.
  • It identifies specific limitations imposed by oncology group protocols.
  • It addresses the inherent reluctance to introduce novel treatments in pediatric patients.

Conclusions:

  • Expanding interventional oncology for pediatric malignancies requires dedicated effort from pediatric radiologists.
  • Collaboration between interventional radiologists and clinical colleagues is crucial.
  • Initiative is needed to bring the benefits of IO to children with cancer.